RAC Takes Teeth Out of DNA Research Rules; Invites Public Comment by Year's End

Boddé, Tineke
October 1981
BioScience;Oct1981, Vol. 31 Issue 9, p632
Academic Journal
The article presents information on the new policy proposed by the Recombinant DNA Advisory Committee (RAC) of National Institutes of Health (NIH), Bethesda, Maryland, to relax the guidelines that have been dominating DNresearch for the last five years. Members approved the proposal to amend the 25-page document by eliminating large sections dealing with responsibilities of investigators and NIH policies on noncompliance. It states that public citizens and professionals are invited to review and comment until December 31, 1981 on a summary report. It is supposed that the issue will come to a final vote at the January 1982 RAC meeting. Approval by the NIH director is needed to make the new policy effective.


Related Articles

  • New DNA Committee Further Eases Research Controls. Henig, Robin Marantz // BioScience;Apr1979, Vol. 29 Issue 4, p213 

    The article presents information on the guidelines by the NIH Recombinant DNA Advisory Committee (known as the RAC). It states that the NIH guidelines would permit recombination of nonhuman DNA with human cells, and would allow such exchanges at the lowest level of physical containment. It...

  • In sickness and in health. Boyce, Nell // New Scientist;10/25/97, Vol. 156 Issue 2105, p20 

    Reports on the impact of gene therapy trials approved by the Recombinant DNA Advisory Committee of the US National Institutes of Health. Debate on the prevention of genetic engineering that changes normal characteristics; Effect of gene therapy on future generations; Risks of altering genetic...

  • Fears mount for gene scrutiny as watchdog faces axe. Kiernan, Vincent // New Scientist;6/08/96, Vol. 150 Issue 2033, p10 

    Reports on the proposed abolition of the US Recombinant DNA Advisory Committee (RAC) that was originally tasked to lay down guidelines for genetic engineering experiments in bacteria. Approval of human gene therapy trials; Transfer of RAC tasks to the Food and Drug Administration and review...

  • NIH review to suggest streamlined handling of gene therapy bids. Taylor, Robert // Nature;6/29/1995, Vol. 375 Issue 6534, p713 

    Reports on the conclusion made by an external advisory panel that the Recombinant DNA Advisory Committee (RAC) of the United States National Institutes of Health (NIH) need not review human gene therapy protocols similar to those already approved. Initial screening of applications to be made...

  • Keeping faith in gene manipulation.  // Nature;7/18/1996, Vol. 382 Issue 6588, p191 

    Asserts that good reasons exist for revising the way the gene therapy experiments receive public scrutiny, but such revision must be done sensitively. The controversial role in the scientific community of the Recombinant DNA Advisory Committee (RAC) of the US National Institutes of Health...

  • US plan to scrap DNA panel splits genetic researchers. Wadman, Meredith // Nature;7/18/1996, Vol. 382 Issue 6588, p197 

    Reports disputes in the American gene-therapy field over a proposal to eliminate the Recombinant DNA Advisory Committee (RAC) of the US National Institutes of Health (NIH). Creation of the committee in the mid-1970s, in response to public fears of genetic engineering; The NIH's view that the...

  • Gene therapy approval may be rocky road for industry. Gavaghan, Helen // Nature;3/16/1995, Vol. 374 Issue 6519, p202 

    Talks about the possibility of a tough relationship to be faced by the biotechnology industry and Recombinant DNA Advisory Committee of the US National Institute of Health as the gene therapy moves down the clinical pipeline in US.

  • NIH panel may increase gene-trial scrutiny. . . Smaglik, Paul // Nature;6/15/2000, Vol. 405 Issue 6788, p724 

    Reports on the urgency of regulations to be placed on clinical trials for gene therapy. Decision made by the United States National Institutes of Health (NIH) to give its Recombinant DNA Advisory Committee (RAC) a greater role in the regulation process; Proposal that trial enrollment be...

  • NIH panel to limit secrecy on gene therapy. Wadman, Meredith // Nature;11/4/1999, Vol. 402 Issue 6757, p6 

    Reports actions taken by the Recombinant DNA Advisory Committee (RAC) to stiffen its guidelines on the reporting of deaths and adverse events in cases involving gene therapy patients. Why the branch of the National Institutes of Health (NIH) felt it needed to stiffen the guidelines; Response of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics